Hemlibra (emicizumab-kxwh) - Drug Insight and Market Forecast - 2030

Publisher Name :
Date: 06-Aug-2020
No. of pages: 80
Delivery of the Report will take 2-3 working days once order is placed.

Overview

"Hemlibra - Drug Insight and Market Forecast—2030" report by DelveInsight outlays comprehensive insights of the product based on routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with Hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. A detailed picture of the Hemlibra in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, United Kingdom), and Japan, for the study period 2017-2030 is provided in this report. The report contains a detailed description of the product covering mechanism of action, dosage and administration, route of synthesis and pharmacological studies, also including product marketed details, regulatory milestones and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins required to activate the natural coagulation cascade and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once weekly, every two weeks or every four weeks. Hemlibra was created by Chugai Pharmaceutical and is being co-developed globally by Chugai, Roche and Genentech. Hemlibra was approved by the FDA in November 2017 for adults and children with haemophilia A with factor VIII inhibitors. In April 2018, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Hemlibra (emicizumab-kxwh) for people with hemophilia A without factor VIII inhibitors. In October 2018, the US Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.

Scope of the report

The report provides insights into:

- A comprehensive product Overview

including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.

- Elaborated details on regulatory milestones and other development activities have been provided in this report.

- The report also highlights the drug marketed details across the United States, Europe and Japan.

- The report also covers the patents information with expiry timeline around Hemlibra (emicizumab-kxwh).

- The report contains historical and forecasted sales for Hemlibra (emicizumab-kxwh) till 2030.

- Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.

- The report also features the SWOT analysis with analyst insights and key findings of Hemlibra (emicizumab-kxwh).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Hemlibra (emicizumab-kxwh) Analytical Perspective by DelveInsight

- In-depth Hemlibra (emicizumab-kxwh) Market Assessment

This report provides a detailed market assessment of Hemlibra (emicizumab-kxwh) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

- Hemlibra (emicizumab-kxwh) Clinical Assessment

The report provides the clinical trials information of Hemlibra (emicizumab-kxwh) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

- In the coming years, the market scenario for Hemlibra (emicizumab-kxwh) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

- The companies and academics are working to assess challenges and seek opportunities that could influence Hemlibra (emicizumab-kxwh) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

- Other approved products for the disease are giving market competition to Hemlibra (emicizumab-kxwh) and launch of late-stage emerging therapies in the near future will significantly impact the market.

- A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Hemlibra (emicizumab-kxwh).

- Our in-depth analysis of the sales data of Hemlibra (emicizumab-kxwh) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Hemlibra (emicizumab-kxwh) in the market.

Key Questions

- What is the prescribed dosage and strengths of Hemlibra (emicizumab-kxwh) are available in the market?

- What are the common adverse reactions or side effects of Hemlibra (emicizumab-kxwh)?

- What is the product type, route of administration and mechanism of action of Hemlibra (emicizumab-kxwh)?

- What are the chemical specifications of Hemlibra (emicizumab-kxwh)?

- How are the clinical trials diversified on the basis of the trial status?

- What is the history of Hemlibra (emicizumab-kxwh), and what is its future?

- What are the marketed details of Hemlibra (emicizumab-kxwh) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

- How many patents have been granted to Hemlibra (emicizumab-kxwh) and when these patents will get expire?

- What are the pros (benefits) and cons (disadvantages) of Hemlibra (emicizumab-kxwh)?

- In which countries Hemlibra (emicizumab-kxwh) got approval and when it gets launched?

- What are the clinical trials are currently ongoing for Hemlibra (emicizumab-kxwh)?

- How the safety and efficacy results determined the approval of Hemlibra (emicizumab-kxwh)?

- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Hemlibra (emicizumab-kxwh) development?

- What are the key designations that have been granted to Hemlibra (emicizumab-kxwh)?

- What is the historical and forecasted market scenario of Hemlibra (emicizumab-kxwh)?

- How is the market trend of Hemlibra (emicizumab-kxwh) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?

- What are the other approved products available and how these are giving competition to Hemlibra (emicizumab-kxwh)?

- Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Hemlibra (emicizumab-kxwh) - Drug Insight and Market Forecast - 2030

Table of Contents

1. Product Overview
1.1. Indication
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4.1 Dosage Forms and Strengths
1.4. Route of Synthesis
1.5. Pharmacology
1.4.2 Pharmacodynamics
1.4.3 Pharmacokinetics
1.6. Adverse Reactions
1.7. Product Snapshot
1.8. Development Milestones of Hemlibra (emicizumab-kxwh)
1.9. Marketed Details
1.4.4 United States
1.4.5 Europe
1.4.6 Japan
1.10. Patent Details
2. SWOT Analysis
2.1. Analyst Views
3. Regulatory Milestones
3.1. Approvals
3.2. Research and Development
3.3. Clinical Trials Information
3.4. Safety and Efficacy
3.5. Product Developmental Activities
4. Market Assessment
4.1. 7MM Market Analysis
4.2. United States
4.3. Europe
4.4. Japan
4.5. Key Findings
5. Market Competitors
6. Emerging Therapies
7. Appendix
7.1. Report Purchase Options

List of Tables

Table 1 Hemlibra (emicizumab-kxwh), Description
Table 2 Hemlibra (emicizumab-kxwh), Trial Diversification
Table 3 Hemlibra (emicizumab-kxwh), Marketed Details United States
Table 4 Hemlibra (emicizumab-kxwh), Marketed Details Europe
Table 5 Hemlibra (emicizumab-kxwh), Marketed Details Japan
Table 6 Patent Details: Hemlibra (emicizumab-kxwh)
Table 7 Hemlibra (emicizumab-kxwh), Clinical Trial Description, 2020
Table 8 Safety and Efficacy Results for Hemlibra (emicizumab-kxwh)
Table 9 Hemlibra (emicizumab-kxwh), 7MM Market Size from 2017 to 2030 (in Million USD)
Table 10 Hemlibra (emicizumab-kxwh), US Market Size from 2017 to 2030 (in Million USD)
Table 11 Hemlibra (emicizumab-kxwh), EU Market Size from 2017 to 2030 (in Million USD)
Table 12 Hemlibra (emicizumab-kxwh), EU5 Market Size from 2017 to 2030 (in Millions USD)
Table 13 Hemlibra (emicizumab-kxwh), Japan Market Size from 2017 to 2030 (in Million USD)
Table 14 Market Competitors
Table 15 Emerging Therapies

List of Figures

Figure 1 The Development Timeline of Hemlibra (emicizumab-kxwh)
Figure 2 Patent Details, Hemlibra (emicizumab-kxwh)
Figure 3 Hemlibra (emicizumab-kxwh), 7MM Market Size from 2017 to 2030 (in Million USD)
Figure 4 Hemlibra (emicizumab-kxwh), US Market Size from 2017 to 2030 (in Millions USD)
Figure 5 Hemlibra (emicizumab-kxwh), EU Market Size from 2017 to 2030 (in Millions USD)
Figure 6 Hemlibra (emicizumab-kxwh), EU5 Market Size from 2017 to 2030 (in Millions USD)
Figure 7 Hemlibra (emicizumab-kxwh), Japan Market Size from 2017 to 2030 (in Millions USD)
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs